Mvasi™ (bevacizumab-awwb) – First-time biosimilar launch

- On July 19, 2019, Allergan and Amgen announced the launch of Mvasi (bevacizumab-awwb), a biosimilar to Genentech's Avastin (bevacizumab).
    - Zirabev™ (bevacizumab-bvzr), Pfizer's biosimilar to Avastin was also FDA approved on June 28, 2019. Pfizer's launch plans for Zirabev are pending.
- Mvasi and Avastin share the following indications:
    - Metastatic colorectal cancer (MCC), in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment
    - MCC, in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen
    - Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment
    - Recurrent glioblastoma in adults
    - Metastatic renal cell carcinoma in combination with interferon alfa
    - Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
- In addition, Avastin is indicated for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- The wholesale acquisition cost (WAC) of Mvasi is $677.40 per 100 mg and $2,709.60 per 400 mg single-dose vial. This is 15% lower than the WAC for Avastin.